VBI Vaccines, Inc. New Common Stock (Canada)
VBIV
VBIV was delisted on the 7th of August, 2024.
62 hedge funds and large institutions have $136M invested in VBI Vaccines, Inc. New Common Stock (Canada) in 2017 Q4 according to their latest regulatory filings, with 21 funds opening new positions, 26 increasing their positions, 3 reducing their positions, and 3 closing their positions.
767% more repeat investments, than reductions
Existing positions increased: 26 | Existing positions reduced: 3
600% more first-time investments, than exits
New positions opened: 21 | Existing positions closed: 3
165% more capital invested
Capital invested by funds: $51.4M → $136M (+$84.6M)
41% more funds holding
Funds holding: 44 → 62 (+18)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PA
Perceptive Advisors
New York
|
+$12.7M |
| 2 |
BI
BVF Inc
San Francisco,
California
|
+$12.7M |
| 3 |
MMH
Menora Mivtachim Holdings
Ramat Gan,
Israel
|
+$10.9M |
| 4 |
EAM
Eventide Asset Management
Boston,
Massachusetts
|
+$7.58M |
| 5 |
HIIFS
Harel Insurance Investments & Financial Services
Ramat Gan,
Israel
|
+$6.72M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FPC
Falcon Point Capital
San Francisco,
California
|
-$318K |
| 2 |
Bank of Montreal
Toronto,
Ontario, Canada
|
-$209K |
| 3 |
CS
Credit Suisse
Zurich,
Switzerland
|
-$57K |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
-$12.9K |
| 5 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$8.73K |
VBIV Hedge Fund Activity: Q4 2017 in Review
62 of the 4,419 institutional investors tracked by Wall St. Rank reported a position in VBI Vaccines, Inc. New Common Stock (Canada) (VBIV) for Q4 2017, worth a combined $136M — up 165% from $51.4M a quarter earlier.
Buyers outnumbered sellers: 21 funds opened new VBIV positions and 3 closed out — a net gain of 18 holders — while 26 added to existing stakes and 3 trimmed.
The largest buyer was Perceptive Advisors, adding an estimated $12.7M. The largest seller was Falcon Point Capital, cutting an estimated $318K.
- 62 institutional investors held VBI Vaccines, Inc. New Common Stock (Canada) (VBIV) as of Q4 2017, up from 44 in Q3 2017.
- Funds reported $136M of VBI Vaccines, Inc. New Common Stock (Canada) stock for Q4 2017, up 165% quarter-over-quarter.
- 21 funds opened new VBI Vaccines, Inc. New Common Stock (Canada) positions in Q4 2017 and 3 closed out, a net change of +18 holders.
- The largest VBI Vaccines, Inc. New Common Stock (Canada) buyer in Q4 2017 was Perceptive Advisors, an estimated $12.7M added.
- The largest VBI Vaccines, Inc. New Common Stock (Canada) seller in Q4 2017 was Falcon Point Capital, an estimated $318K sold.
Based on aggregated 13F filings for Q4 2017.